Abstract:Abstract Introduction: Piezo1 is a transmembrane protein, forming a mechano-sensitive ion channel. Piezo channels play an important role in mechano-sensing and mechano-transduction. Stretch activation of Piezo channels lead to influx of cations and activation of additional Ca2+ channels and depolarization. There are early evidences that Piezo1 channel signaling alters cancer cell behavior. It promotes migration in breast cancer cells, migration and chemo-resistance in gastric cancer cells, invasion of osteosarcoma cells, and enhances cell survival in synovial sarcoma cells. Contrary, lower level of Piezo1 associates with more invasive phenotype in lung cancer. In this study, we aimed to investigate clinical relevance of Piezo1 expression in breast cancer. Methods: In order to investigate Piezo1 clinical relevance in breast cancer patients, we used The Cancer Genome Atlas (TCGA) breast cancer cohort as a testing cohort, and GSE3494 as validation cohort. Piezo1 expression levels were compared among different stages as well as breast cancer subtypes. Patients’ survival was compared based on Piezo1 expression in each subtype. Gene set enrichment analysis (GSEA) and cibersort algorithms were used to evaluate pathways and infiltrating immune cells associated with PIEZO1 expression. Results: There was no significant difference in PIEZO1 expressions based on AJCC stage (P=0.258). PIEZO1 expression was significantly higher in the hormone receptor (HR)-negative (both estrogen receptor (ER)- and progesterone receptor (PR)-negative) tumors (P<0.001), whereas, there was no significant difference between HER2-positive and -negative tumors (P=0.279). When we compared patient survival based on PIEZO1 expression, there was no significant difference in the whole breast cancer cohort (disease-free survival (DFS); P=0.201, overall survival (OS); P=0.694). On the other hand, high PIEZO1 expression showed significantly worse prognosis for both DFS (P=0.033) and OS (P=0.002) in the HR-negative cohort, but not in HR-positive cohort (DFS; P=0.995, OS; P=0.083). These findings were validated in validation cohort GSE3494, in which PIEZO1 expression was higher in the HR-negative patients as compared to its counterpart (P=0.006) and higher PIEZO1 showed worse prognosis in the HR-negative cohort (P=0.003). As possible mechanisms, GSEA revealed that PIEZO1 high expression tumor was associated with cancer aggressiveness characteristics, such as epithelial-mesenchymal transition (EMT) (P<0.001) and hypoxia (P<0.001) in HR-negative breast cancer. Further, PIEZO1 high expressing tumor has less anti-cancer immune cells, including activated CD4+ memory T cells (P=0.020) and CD8+ T cells (P=0.002). Conclusion: We found that PIEZO1 high expression was associated with poor prognosis in HR-negative breast cancer patients. It may be due to promoted EMT and hypoxic condition, as well as less immunogenic characteristics. Citation Format: Eriko Katsuta, Kazuaki Takabe, Mateusz Opyrchal. Piezo1 is associated with worse prognosis along with promoted epithelial-mesenchymal transition and hypoxia as well as less anti-cancer immune cells in hormone receptor (HR)-negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-23.

Piezo2 Protein: A Novel Regulator of Tumor Angiogenesis and Hyperpermeability

A Feedforward Mechanism Mediated by Mechanosensitive Ion Channel PIEZO1 and Tissue Mechanics Promotes Glioma Aggression.

Prognosis and clinical significance of Piezo2 in tumor: a meta-analysis and database validation

Pleiotropic physiological functions of Piezo1 in human body and its effect on malignant behavior of tumors

Piezo1 (Piezo-Type Mechanosensitive Ion Channel Component 1)-Mediated Mechanosensation in Macrophages Impairs Perfusion Recovery after Hindlimb Ischemia in Mice

Piezo1 regulates migration and invasion of breast cancer cells via modulating cell mechanobiological properties

STEM-26. BLOOD-TUMOR BARRIER IS COMPOSED OF MECHANOSENSING TUMOR CELLS THAT MASK THERAPEUTIC VULNERABILITY

Mechanosensitive Channel Piezo1 Induces Cell Apoptosis in Pancreatic Cancer by Ultrasound with Microbubbles.

Identification of PIEZO1 as a potential prognostic marker in gliomas

PIEZO1 acts as a cancer suppressor by regulating the ROS/Wnt/β‐catenin axis

Piezo1 mediates angiogenesis through activation of MT1-MMP signaling.

PIEZO2 expression is an independent biomarker prognostic for gastric cancer and represents a potential therapeutic target

The mechanoreceptor PIEZO1 is a novel oncogene in glioma by promoting astrocyte reactivity

Mechanosensitive Ion Channel PIEZO1 Signaling in the Hall-Marks of Cancer: Structure and Functions

Five Mirnas-Mediated PIEZO2 Downregulation, Accompanied with Activation of Hedgehog Signaling Pathway, Predicts Poor Prognosis of Breast Cancer.

Piezo1: the Key Regulators in Central Nervous System Diseases

Effect of Piezo1 Overexpression on Peritumoral Brain Edema in Glioblastomas.

Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients

Abstract P4-07-23: Piezo1 is associated with worse prognosis along with promoted epithelial-mesenchymal transition and hypoxia as well as less anti-cancer immune cells in hormone receptor (HR)-negative breast cancer

The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment

Knockdown of Angiopoietin-Like Protein 2 Inhibits Proliferation and Invasion in Glioma Cells Via Suppressing the ERK/MAPK Signaling Pathway.